SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026)
SAB Biotherapeutics (SABS) reported Receivables - Accured of $1.6 million for Q1 2026, up 7171.4% on a YoY basis from $21386.0 in Q1 2025, and up 64.25% quarter-over-quarter from $946781.0 in Q4 2025.
SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Receivables - Accured for 3 years, with the latest figure at $1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Accured rose 7171.4% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 7171.4% YoY), and the FY2025 full-year result was $946781.0, up 846.78% from the prior year.
- Receivables - Accured for Q1 2026 stood at $1.6 million, up from $946781.0 in the prior quarter.
- The five-year high for Receivables - Accured was $1.6 million in Q1 2026, with the low at $21386.0 in Q1 2025.
- Historically, Receivables - Accured has averaged $462303.9 across 3 years, with a median of $209078.0 in 2024.
- Annual changes were most pronounced in 2025 — Receivables - Accured tumbled 88.93% — and 2026, when it surged 7171.4%.
- SAB Biotherapeutics' Receivables - Accured stood at $100000.0 in 2024, then surged by 846.78% to $946781.0 in 2025, then jumped by 64.25% to $1.6 million in 2026.
- The last three Receivables - Accured figures came in at $1.6 million (Q1 2026), $946781.0 (Q4 2025), and $560000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.56 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 946,781.00 |
| Dec 31, 2025 | 946,781.00 |
| Sep 30, 2025 | 560,000.00 |
| Sep 30, 2025 | 560,000.00 |
| Mar 31, 2025 | 21,386.00 |
| Mar 31, 2025 | 21,386.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 97,047.00 |
| Sep 30, 2024 | 97,047.00 |
| Jun 30, 2024 | 224,924.00 |
| Jun 30, 2024 | 224,924.00 |
| Mar 31, 2024 | 193,232.00 |
| Mar 31, 2024 | 193,232.00 |